Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996 Nov;156(5):1606-8 PMID: 8863548
Pubmed ID
8863548Abstract
PURPOSE: We evaluated the role of paclitaxel in patients with advanced urothelial carcinoma and renal insufficiency or as second line therapy for metastatic disease.
MATERIALS AND METHODS: Nine patients with advanced urothelial carcinoma received 175 to 250 mg./m2. paclitaxel intravenously as a 24-hour infusion. Six patients had renal insufficiency with a median serum creatinine of 2.25 mg./dl. (range 1.9 to 3.2) and 3 with normal renal function were treated after disease progression following 1 to 2 prior chemotherapy regimens.
RESULTS: Of 9 patients 5 (56%) achieved a partial response, including 4 of 6 with renal insufficiency. Toxicity was primarily hematological with 4 patients experiencing febrile neutropenia. There was no adverse impact on renal function.
CONCLUSIONS: Paclitaxel as a single agent represents an effective therapeutic alternative for patients with advanced transitional cell carcinoma of the urothelium and renal insufficiency precluding cisplatin or gallium nitrate based chemotherapy. Additionally, paclitaxel appears to be effective in patients in whom prior cisplatin based therapy failed.
Author List
Dreicer R, Gustin DM, See WA, Williams RDAuthor
William A. See MD Chair, Professor in the Urologic Surgery department at Medical College of WisconsinScopus
2-s2.0-0029853721 89 CitationsMESH terms used to index this publication - Major topics in bold
AdultAged
Antineoplastic Agents, Phytogenic
Carcinoma, Transitional Cell
Humans
Male
Middle Aged
Neoplasm Staging
Paclitaxel
Renal Insufficiency
Salvage Therapy
Urinary Bladder Neoplasms
Urothelium
